US 12,083,151 B2
Synergistic bacterial compositions and methods of production and use thereof
Matthew R. Henn, Somerville, MA (US); Geoffrey von Maltzahn, Boston, MA (US); Anthony Mario D'Onofrio, Northborough, MA (US); Kevin Daniel Litcofsky, Boston, MA (US); David Arthur Berry, Brookline, MA (US); David N. Cook, Brookline, MA (US); Noubar B. Afeyan, Lexington, MA (US); and John Grant Aunins, Doylestown, PA (US)
Assigned to Seres Therapeutics, Inc., Cambridge, MA (US)
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
Filed on Oct. 5, 2022, as Appl. No. 17/938,184.
Application 17/938,184 is a division of application No. 17/120,671, filed on Dec. 14, 2020, granted, now 11,464,812.
Application 17/120,671 is a division of application No. 16/223,008, filed on Dec. 17, 2018, granted, now 10,864,235, issued on Dec. 15, 2020.
Application 14/221,190 is a division of application No. 14/091,201, filed on Nov. 26, 2013, granted, now 8,906,668, issued on Dec. 9, 2014.
Application 16/223,008 is a continuation of application No. 15/359,439, filed on Nov. 22, 2016, abandoned.
Application 15/359,439 is a continuation of application No. 14/592,481, filed on Jan. 8, 2015, granted, now 9,533,014, issued on Jan. 3, 2017.
Application 14/592,481 is a continuation of application No. 14/221,190, filed on Mar. 20, 2014, granted, now 9,028,841, issued on May 12, 2015.
Application 14/091,201 is a continuation of application No. PCT/US2013/071758, filed on Nov. 25, 2013.
Claims priority of provisional application 61/729,518, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,519, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,520, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,521, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,522, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,524, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,525, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,526, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,527, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,515, filed on Nov. 23, 2012.
Claims priority of provisional application 61/729,517, filed on Nov. 23, 2012.
Prior Publication US 2023/0226126 A1, Jul. 20, 2023
Int. Cl. A61K 39/02 (2006.01); A23L 33/10 (2016.01); A23L 33/135 (2016.01); A23P 10/30 (2016.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/74 (2015.01); A61K 35/742 (2015.01); A61K 38/13 (2006.01); A61K 39/08 (2006.01); A61K 45/06 (2006.01)
CPC A61K 35/742 (2013.01) [A23L 33/127 (2016.08); A23L 33/135 (2016.08); A23P 10/30 (2016.08); A61K 9/0053 (2013.01); A61K 9/4891 (2013.01); A61K 35/74 (2013.01); A61K 38/13 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A composition comprising a first species of isolated bacterium, a second species of isolated bacterium, and a capsule; wherein the first species is Clostridium symbiosum and the second species is Clostridium orbiscindens; wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548, wherein the first species and the second species are capable of inhibiting Clostridium difficile (C. difficile) growth as measured by a CivSim assay; and wherein the capsule encapsulates the first species and the second species.